



SPONSORS

PLATINUM



GOLD

NOVATEK CATUG

SILVER



MEDIA PARTNERS














SPONSORED BY






GENNAP SUMMIT

On the APT track you will learn about environmental monitoring systems, facility cleaning and disinfectant qualification, aseptic cleanroom operations, filtration, sterilization, aseptic process simulation, and regulatory requirements. Further discussions at the GCT Track we will focussing on vector improvement for both ex vivo and in vivo approaches, dedicated sessions on CMC strategy, analytical development and qualification, product-related impurities and their link to quality, bioassays, comparability, stability, formulation, and the emergence of nonviral gene therapies.

KEY PRACTICAL POINTS



GCT TRACK

- · Requirements in bringing drugs to market
- Vector serotypes to produce more durable gene expression
- Vector Design and Development for Gene and Cell Therapies
- Current challenges and future of gene therapy technical development
- Lessons learnt from commercial products/ late-stage products
- The complexity of vector development ٠ and production
- Investors perspective of gene therapy development
- Reducing timelines for cell and gene therapy drug development
- CMC strategies for rare diseases
- Qualifying starting materials/intermediary materials
- Developing novel vectors to reduce immunogenicity
- Successful strategies to accelerate CGT process development from preclinical to manufacturing and commercialisation
- Efficient enabling novel technologies and resources
- Defining optimal regulatory pathways


· Critical elements of establishing a robust CMC strategy Identifying and measuring of CQAs and determining CPPs • Crucial factors in easing the complexity of vector development and production Achieving technical, regulatory, and cost efficiency for manufacturing safe gene and cell therapy products • Critical aspects of establishing an efficient, consistent, and flexible CMC strategy • Controlling a product's CQAs by controlling the process' CPPs Emerging technologies improving effectiveness and CGTPs manufacturing processes and production · Crucial components of controlling and scaling manufacturing process and operations for CGTPs • Development of Pediatric Gene Therapy Using Nuclease-Free Genomic Editing Technology

•

APT TRACK

- The Evolution of Aseptic Technologies
- Cleanrooms for the Annex 1 updates
- Implementation of quality risk
 management
- Regulatory framework
- Antibody Drug Conjugates / HPAPIs
 production
- Lyophilization of highly potent products and aseptic processing.
- Occupational safety requirements
- Aseptic process development, validation and evaluation.
- Highly potent facility design and engineering considerations
- Isolator Technology use in aseptic processing for loss minimization/ elimination.
- Overcoming technical challenges in decontamination processes and material transfers.
- Cleaning and disinfection programs for aseptic facilities.
- Cross contamination prevention and control for highly potent products.
- Robotics in aseptic processing
- Gloveless Isolators and dose control

- ADC/HPAPI aseptic processing fill and finish
- Challenges for manufacturers in cell and gene therapy production systems
- Airflow visualization for contamination risks assessment.
- Implementing containment technologies
 in aseptic processing
- Boosting sterilization: successful strategies, advanced technologies implementation.
- Cleaning automation and technologies.
- Gowning: procedures, training, personnel qualification.
- Microbiology techniques use in aseptic processing.
- Integrating sanitization techniques to empower contamination control.
- Filtration: filter integrity testing in aseptic processing.
- Single-use systems implementation.
- Assess airflow visualization to limit risk
 for product contamination
- Describe the importance of filter integrity testing for aseptic operations



SPEAKERS



Alison Armstrong Senior Director, Global Head Technical and Scientific Solutions at Merck KGaA



Chris Berridge Global Technical Consultant, Bioquell Specialist *at Ecolab Life Sciences*



Christiane Niederlaender Vice President Technical CMC at Parexel



David Estapé Senior Process Specialist & Senior Fellow at CRB




Michele Simone Corporate Quality Management Director *at Bracco*



Richard Denk Senior Consultant

Aseptic Processing & Containment at SKAN AG



Donald Singer Senior Microbiology Technical Consultant *at Ecolab Life Sciences*



Edith Filaire Professor and Scientific Director *at ICARE GROUP*



Fabian Stutz CEO *at Pharmabotix AG*



Frank J.T. Staal Professor at Leiden University Medical School



Zhihao Peter Qiu External Advocacy Lead China *at Roche Genentech*



Zsuzsanna Izsvák Group leader at Max Delbrück Center of Molecular Medicine, Berlin



Gregory Fiore

Chief Executive Officer at Exacis Biotherapeutics



James Drinkwater Head of GMP Compliance at Franz Ziel




Juha Mattila Director, Sterilization Technologies at STERIS Life Sciences



Magnus Gustafsson Chief Business Officer at Biovian







Silvia Aldi Product Manager for Cell & Gene Therapy at SKAN AG



Susan Cleary Director Product Development at Novatek International



DAY 1 FEBRUARY 23, 2023

APT TRACK

8:00 - 8:30

Registration and Welcome Coffee

8:30 - 9:00

Annex 1 - GMP Compliance when working with Robotics in Aseptic Processing

By **Richard Denk**, Senior Consultant Aseptic Processing & Containment at SKAN AG

9:00 - 9:30

Aseptic processing applied in Gene & Cell therapy following QRM principles

By **James Drinkwater**, Head of GMP Compliance at Franz Ziel

9:30 - 10:00

Speed Networking

10:00 - 10:30 Morning Coffee-Break

10:30 - 11:00

Modular and Flexible Robotics Systems for CGT

By Fabian Stutz, CEO at Pharmabotix AG

11:00 - 11:30

FDA's Regulatory Review and Inspection of Biological Products Manufactured Using Aseptic Processing

By **Zhihao Peter Qiu**, External Advocacy Lead China at Roche Genentech

11:30 - 12:00 Protak Scientific Presentation

12:00 - 13:00

Pall Corporation Presentation

13:00 - 14:00

Lunch & Networking Break



GCT TRACK

14:00 - 14:30

Developing stem cell-based gene therapy for RAG1 and RAG2 deficient SCID

By **Frank J.T. Staal**, Professor at Leiden University Medical School

14:30 - 15:00

Topic to be announced - Zsuzsanna Izsvák By **Zsuzsanna Izsvák**, Group leader at Max Delbrück Center of Molecular Medicine, Berlin

15:00 - 15:30

Comparability for genetically modified cells: challenges for vectors and cells

By **Christiane Niederlaender**, Vice President Technical CMC at Parexel

15:30 - 16:00

CMC considerations for Cell and Gene therapy products *By Alison Armstrong, Senior Director, Global Head Technical and Scientific Solutions at Merck KGaA*

16:00 - 16:30

Afternoon Coffee Break

16:30 - 17:30

Panel Discussion

• Ensuring clinical success: Clinical data generation

• The future and commercial sustainability of ATMPs

• ATMP – Regulatory, process and supply chain: Challenges & opportunities

CGT Bioprocessing and digitalization

• Viral-Vector Therapies at scale: today's Challenges and future opportunities Panelists: Alison Armstrong; Gregory Fiore; Zsuzsanna Izsvák; Christiane Niederlaender

Moderated by **Silvia Aldi**, Product Manager for Cell & Gene Therapy at SKAN AG

17:30

Chairperson Closing Remarks and end of the 1st day sessions

19:30

Gala dinner



DAY 2 FEBRUARY 24, 2023

APT TRACK

8:30 - 9:00 Registration and Welcome Coffee

9:00 - 9:30

Contamination Control with Efficiency – Integrating Annex 1, Automation and Microbiology

By **Donald Singer** | **Chris Berridge**, Ecolab Life Sciences

9:30 - 10:00

Vaporized hydrogen peroxide (VHP) sterilization and biodecontamination technologies – implications from new regulatory and standards developments (EU Annex 1:2022 and ISO 22441:2022) *By Juha Mattila, Director Sterilization Technologies at STERIS Life Sciences*

10:00 - 10:30

Morning Coffee-Break



10:30 - 11:00 Microbial data investigations and effective implementation roadmap of Contamination Control Strategy

By **Michele Simone**, Corporate Quality Management Director at Bracco

11:00 - 11:30

Pattern Recognition and Trending for Regulatory Compliancy and Contamination Control Strategy

By **Susan Cleary**, Director Product Development at Novatek International

11:30 - 12:00

The Facility Evolution of Small-Scale Cell Therapy

By **David Estapé**, DSenior Process Specialist & Senior Fellow at CRB

12:00 - 13:00

Panel Discussion

• EU GMP Annex 1 Revision Implementation

- Aseptic Packaging Sustainability
- Contamination Control Strategies

Panelists: James Drinkwater; Zhihao Peter Qiu; Fabian Stutz; Michele Simon

Moderated by Richard Denk

13:00 - 14:00

Lunch & Networking Break

GCT TRACK

14:00 - 14:40

Introduction to Cell and Gene Therapy market | ATMP manufacturing | Validated Cell and Gene Therapy processes in isolators

By **Silvia Aldi**, Product Manager for Cell & Gene Therapy at SKAN AG

14:30 - 15:00

Viral vector development and manufacture By **Magnus Gustafsson**, Chief Business Officer at Biovian

15:00 - 15:30

Alternative in vitro models to animal testing : what are the new challenges and opportunities? By Edith Filaire, Professor and Scientific Director at ICARE GROUP

15:30

Chairperson Closing Remarks and end of the GENAP Summit

REGISTRATION

Package Name

ANGA HIP PACKAGES

Title: Title: Name: Name: Position: Position: E-mail: E-mail: Postcode: Company: Phone: Address: City: Date: dd mm уууу VAT No.: Signature: This booking is invalid without signature **Diogo Lino Ribeiro** EM:diogo.ribeiro@epmgroup.org PH:+351 915 239 640 Project Director, Europe | Porto Office * Please send the signed form to this contact. ACADEMIC/NPO/INVESTOR **INDUSTRY PACKAGE** Individual or Group Registration Individual or Group Registration 2-Days Access 2-Days Access Full Access to Exhibition Area Full Access to Exhibition Area Full Access to all sessions Full Access to all sessions Coffee Breaks & Lunches **Coffee Breaks & Lunches** Poster Presentation Submission Poster Presentation Submission 365 days access on 365 days access on SocioPharma.com SocioPharma.com Pre-Conference Pre-Conference **Cocktail Reception Cocktail Reception** Gala Diner Gala Diner **BOOK NOW BOOK NOW** Until 23rd December 2022 Until 13th February 2022 Until 13th January 2022 Academic / NPO / Investor 950€ 1050€ 1150€ Industry Package 1699€ 1799€ 1995€

*The Gennap Summit is an exclusive limited seat event.

Team Discounts

3 Delegates	4050€
4 Delegates	5400€
5 Delegates	6750€

SPON	1501	KSH
GOLD SPONSORSHIP	(VAT INC.)	6500€
2-Days Full Access to the GENAP Sun 6m2 exhibition space with table and 3 1/4 page Ad in conference program Logo on the conference website and r Logo on Conferece Notebooks & Bags Logo on Gala Dinner Menu Logo Display in all conference areas Flyer/promo gifts into congress bags Branding at post-event communicatio Pre-Conference Cocktail Reception Gala Dinner Coffee Breaks & Business Lunches 3 delegates has admission Extra delegate registration for only €1 Poster Presentation Submission 365 days access on SocioPharma.com	3 chairs main stage s on activities 000	
PLATINUM SPONSORSHIP	(VAT INC.)	8950€
2-Days Full Access to the GENAP Sun Speaking Slot [up to 40min] 8m2 exhibition space with table and 2 Monitor stand. 1/2 page Ad in conference program Logo on the conference website and r Logo on Conferece Notebooks Logo Display in all conference areas Main Sponsor for Pre-Conference Coo Dinner Flyer/promo gifts into congress bags Branding at post-event communicatio Pre-Conference Cocktail Reception Gala Dinner Coffee Breaks & Business Lunches 4 delegates has admission Extra delegate registration for only €1 Poster Presentation Submission 365 days access on SocioPharma.com	2 chairs with main stage oktail Recept on activities 000	
		ONLINE
lin	til 23rd Decer	nber 2022

Silver	4500€
Gold	5500€
Platinum	7500€

By sending this form, I confirm that I have read and accepted the terms and conditions detailed below

Confirmation

While every reasonable effort will be made to adhere to the advertised package, EPM Group reserves the right to change event dates, sites or location, omit event features, or merge the event with another event as it deems necessary without penalty and in such situations no refunds, We will confirm your participation after receiving the signed registration form the delegate will part refunds or alternative offers shall be made (including, but not limited to any force majeure receive the invoice within 24h of sending the signed form. The hotel details will be sent 2 or 3 occurence) and provided that the event is not postponed to a later date nor is it merged with weeks before the start of the conference. another event, the client shall receive a credit note for the amount that the client has paid to such Cancellations permanently canceled event. No refunds, part refunds or alternative offers shall be made. Cancellations made one month prior to the start of the conference will be refunded less 50%

Copyright administration charge. Refunds will be made after the conference. Cancellations made within All Intellectual Property rights in all materials produced or distributed by EPM Group in connection

one month of the conference start date will receive no refund. Substitutes are accepted up to 3 days before the conference. Any cancellation will be accepted latest one month before the event and should be informed in written form.

SILVER SPONSORSHIP

(VAT INC.) **5500€**

- 2-Days Full Access to the GENAP Summit
- Speaking Slot [up to 30min] •
- Logo on the conference website and main stage •
- Logo on Conference notebooks & bags
- Logo Display in all conference areas •
- Flyer/promo gifts into congress bags •
- Branding at post-event communication activities
- Pre-Conference Cocktail Reception
- Gala Dinner .
- Coffee Breaks & Business Lunches .
- 2 delegates has admission (1 Speaker + 1 Delegate)
- Extra delegate registration for only €1000 .
- Poster Presentation Submission •
- 365 days access on SocioPharma.com

to register as sponsor



Until 13th January 2022	Until 13th February 2022
4950€	5500€
5950€	6500€
7950€	8950€

Force Majeure

with this event are expressly reserved and any unauthorized duplication, publication or distribution is prohibited.




MELIÃ MILAN0****




The charm of Milanese elegance

Milan is a vibrant city, capital of fashion, glamour and the latest trends. The booming district of Zona Lotto is home to the Meliá Milano. Fully renovated, it reflects the innovative design and elegance for which the capital of Lombardy is famous and also offers facilities that can only be admired. Exclusive suites and rooms plus the added benefits of The Level service.







C G c genapsummit.com